HLA-B and myeloid sarcoma: Our study identified strong interactions between HLA-B and HLA-DRB1, the major MS susceptibility gene and a known target of Glatiramer, supporting the complex involvement of both proteins in relevant MS processes and suggesting HLA-B as a potential target.